Wide Ranks

IPSC

Century Therapeutics, Inc.

1.63

Top Statistics
Market Cap 138 M Forward PE -0.8917 Revenue Growth 434.50 %
Current Ratio 10.39 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.0420 Enterprise / Revenue -1.83 Price To Sales Trailing12 Months 51.64
Profitability
Profit Margins 0.00 % Operating Margins -4398.10 %
Balance Sheet
Total Cash 198 M Total Cash Per Share 2.33 Total Debt 54 M
Total Debt To Equity 27.90 Current Ratio 10.39 Book Value Per Share 2.31
All Measures
Short Ratio 547.00 % Message Board Id finmb_626518430 Shares Short Prior Month 3 M
Return On Equity -0.6261 City Philadelphia Uuid f95000f0-82eb-31c4-9606-6aa49d9bac06
Previous Close 1.35 First Trade Date Epoch Utc 1 B Book Value 2.31
Beta 1.42 Total Debt 54 M Volume 1 M
Price To Book 0.7059 Fifty Two Week Low 1.14 Total Cash Per Share 2.33
Total Revenue 2 M Shares Short Previous Month Date 1 B Target Median Price 11.50
Max Age 86400 Recommendation Mean 1.57 Sand P52 Week Change 0.3133
Operating Margins -4398.10 % Target Mean Price 9.67 Net Income To Common -129891000
Short Percent Of Float 0.0325 Implied Shares Outstanding 85 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 673810 Average Volume10days 673810
Total Cash 198 M Next Fiscal Year End 1 B Revenue Per Share 0.0370
Held Percent Insiders 0.2836 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.35 Target Low Price 5.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.44 Open 1.36
Free Cashflow -62053752 State PA Dividend Yield 0.00 %
Return On Assets -0.2090 Time Zone Short Name EST Trailing Eps -1.83
Day Low 1.35 Address1 25 North 38th Street Shares Outstanding 85 M
Price Hint 4 Target High Price 12.00 Website https://www.centurytx.com
52 Week Change 0.1898 Average Volume 421975 Forward Eps -1.35
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 1006.40 %
Is_sp_500 False Regular Market Day High 1.63 Profit Margins 0.00 %
Debt To Equity 27.90 Fifty Two Week High 5.51 Day High 1.63
Shares Short 2 M Regular Market Open 1.36 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -1.83 Revenue Growth 434.50 %
Shares Percent Shares Out 0.0266 Operating Cashflow -112142000 Currency USD
Time Zone Full Name America/New_York Market Cap 138 M Is_nasdaq_100 False
Zip 19104 Quote Type EQUITY Industry Biotechnology
Long Name Century Therapeutics, Inc. Regular Market Day Low 1.35 Held Percent Institutions 0.5950
Current Price 1.63 Address2 11th Floor Enterprise To Ebitda 0.0420
Financial Currency USD Current Ratio 10.39 Industry Disp Biotechnology
Number Of Analyst Opinions 6 Country United States Float Shares 28 M
Two Hundred Day Average 2.61 Enterprise Value -4918661 Price To Sales Trailing12 Months 51.64
Forward PE -0.8917 Regular Market Volume 1 M Ebitda -117932000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.

Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.

The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors.

In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma.

The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.